CN1682703A - Sterilizing gel - Google Patents

Sterilizing gel Download PDF

Info

Publication number
CN1682703A
CN1682703A CN 200510053904 CN200510053904A CN1682703A CN 1682703 A CN1682703 A CN 1682703A CN 200510053904 CN200510053904 CN 200510053904 CN 200510053904 A CN200510053904 A CN 200510053904A CN 1682703 A CN1682703 A CN 1682703A
Authority
CN
China
Prior art keywords
gel
chlorhexidine
weight amount
total formulation
formulation weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200510053904
Other languages
Chinese (zh)
Other versions
CN1301106C (en
Inventor
贝庆生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEI'S PHARMACEUTICAL Co LTD GUANGZHOU
Original Assignee
BEI'S PHARMACEUTICAL Co LTD GUANGZHOU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEI'S PHARMACEUTICAL Co LTD GUANGZHOU filed Critical BEI'S PHARMACEUTICAL Co LTD GUANGZHOU
Priority to CNB2005100539041A priority Critical patent/CN1301106C/en
Publication of CN1682703A publication Critical patent/CN1682703A/en
Application granted granted Critical
Publication of CN1301106C publication Critical patent/CN1301106C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to sterilizing gel, and sterilizing gel containing chlorhexidine or its physiologically acceptable salt as active component. The sterilizing gel contains also stuffing, excipient, synergist and pH regulator.

Description

A kind of sterilizing gel
Technical field
The present invention relates to a kind of sterilizing gel, especially relate to and contain the sterilizing gel that active component is chlorhexidine or its physiologically acceptable salt.
Technical background
Women self physiological environment has particularity, and vagina and vulva portion is warm and moist, is fit to very much the breeding of multiple pathogenic microorganism, causes various gynecological inflammations and abnormal flavour.According to data, 80% adult women will suffer from gynecological inflammation in life one to twice, and wherein the most commonly vaginitis and cervical disease also have chlamydia, mycoplasma infection.Because of clear water can't thoroughly be removed secretions and dirt, so wreaking havoc also of pathogenic microorganism just can hardly be avoided.
Chlorhexidine (hibitane), chemical name 1,6-pair (just-to the chlorobenzene biguanide) hexane, have another name called two chlorobenzene biguanide.Belong to lower toxicity, embarrass absorption of human body, human body skin is not had the obvious stimulation effect.In the working concentration scope, be a kind of desirable disinfectant of nontoxic, non-stimulated and few sensitization as skin, mucosa disinfectant.Chlorhexidine (hibitane) is efficient, wide-spectrum bactericide, can kill Gram-negative and gram-positive bacterium brood body, and Mlc is low, and some fungus and bacterial spore are had bacteriostasis.This medicine with can cause the semi permeability of film to be destroyed rapidly by the absorption of the positive charge on the cell serous coat after antibacterial contacts, the thalline content condenses, and reaches the sterilization purpose.Chlorhexidine (hibitane) is widely used in skin degerming, mucosa sterilization, wound surface sterilization, surface disinfection.Aspect Amino-Cerv, chlorhexidine (hibitane) action range, not only effective to colpitis simplex, all effective to antibacterial, mycete, infusorian, gonorrhea etc.Chlorhexidine (hibitane) is to integrate antibacterial, sterilization, anticorrosion medicine for external use.More superior than other simple property externally-applied female medicines.
Treatment vaginal bacteria such as clinical chlorhexidine commonly used (hibitane) suppository, washing liquid and fungal infection (as purulent vaginitis, colpitis mycotica, cervical erosion) also are used for the treatment of trichomonal vaginitis, have obtained clinical effectiveness preferably.Also useful chlorhexidine (hibitane) liniment treatment cervicitis also obtains satisfied curative effect.In addition, because of unsuitable vagina lavation of pregnancy period, unsuitable oral metronidazole and nystatin medicine can adopt chlorhexidine (hibitane) liquid topical therapeutic.Finding in the therapeutic process that this medicine can reduce patient leucorrhea amount, ease the pain and pruritus vulvae, is a kind of safe and reliable medicine.
Be used for the treatment of and prevent chlorhexidine (hibitane) the local application dosage form of gynecological inflammation existing a lot of at present, as solution, suppository, liniment etc.Comparatively speaking, solution uses inconvenient, and tack is poor, to such an extent as to influence therapeutic effect; And suppository, liniment patient's toleration is relatively poor, sometimes pollution clothes.And gel of the present invention solves these problems.
Summary of the invention
The present invention finds, gives chlorhexidine with the form of gel, can increase curative effect and patient's toleration.
Sterilizing gel of the present invention, it by chlorhexidine or its physiologically acceptable salt and the medicine acceptable carrier that is fit to make gel form.
Gel of the present invention, the physiologically acceptable salt of wherein said chlorhexidine is chlorhexidine acetate and chlorhexidine gluconate.
Gel of the present invention, wherein said carrier comprise filler, forming agent, synergist and pH regulator agent.
Gel of the present invention, wherein said forming agent is selected from one or more in tragakanta, gelatin, starch, cellulose derivative, carbopol and the sodium alginate, preferred cellulose derivant, most preferably hydroxyethyl-cellulose and hydroxypropyl methylcellulose.
The wherein said synergist of gel of the present invention is selected from ethanol, isopropyl alcohol, propylene glycol and pentanediol.Preferred alcohol, isopropyl alcohol, most preferred ethanol.
The wherein said pH regulator agent of gel of the present invention is selected from lactic acid, citric acid, tartaric acid, malic acid, succinic acid, 1,3-propanedicarboxylic acid, maleic acid, glutamic acid, mandelic acid, fumaric acid, one or more in the phosphoric acid.Preferred lactic acid, citric acid, most preferably lactic acid.
Gel of the present invention, preferably by chlorhexidine or its physiologically acceptable salt and hydroxyethyl-cellulose, ethanol, lactic acid is formed, wherein, chlorhexidine or its physiologically acceptable salt account for the 0.01%-5% of total formulation weight amount, and hydroxyethyl-cellulose accounts for the 0.2%-20% of total formulation weight amount, ethanol accounts for the 0.2-20% of total formulation weight amount, and lactic acid accounts for the 0.001-0.1% of total formulation weight amount.
Gel of the present invention, preferably by chlorhexidine or its physiologically acceptable salt and hydroxypropyl methylcellulose, ethanol, lactic acid is formed, wherein, chlorhexidine or its physiologically acceptable salt account for the 0.01%-5% of total formulation weight amount, and hydroxypropyl methylcellulose accounts for the 0.2%-20% of total formulation weight amount, ethanol accounts for the 0.2-20% of total formulation weight amount, and lactic acid accounts for the 0.001-0.1% of total formulation weight amount.
Gel of the present invention, more preferably, wherein, chlorhexidine or its physiologically acceptable salt account for the 0.5-5% of total formulation weight amount, hydroxypropyl methylcellulose or hydroxyethyl-cellulose account for the 0.5-5% of total formulation weight amount, ethanol accounts for the 0.5-5% of total formulation weight amount, and lactic acid accounts for the 0.002-0.01% of total formulation weight amount.
The chlorhexidine physiologically acceptable salt also can be selected from hydrochlorate.Filler in the carrier is a water.
The present invention provides the method for preparing gel of the present invention simultaneously.It is the conventional preparation technology of gel: comprise chlorhexidine or its physiologically acceptable salt are added in the synergist by a certain percentage stirring and dissolving; Forming agent is added heated and stirred dissolving extremely fully in the purified water, be heated to about 85 ℃, be incubated about 30 minutes, stir, be cooled to about 60 ℃, add the pH regulator agent, adjust pH, stir, be cooled to about 45 ℃, add the chlorhexidine of preparation in advance or the synergist solution of its physiological acceptable salt, be cooled to about 35 ℃, stirred 30 minutes, and detected appearance transparent and do not have behind the granule.
Gel of the present invention can be used for treatment and prevention gynecological inflammation, as: various vaginitiss, pruritus vulvae, cervicitis etc.
Gel of the present invention, the preparation of particularly preferred prescription composition shows that through a large amount of experiments curative effect strengthens, side effect reduces, good stability, prescription is reasonable, and easy to use, technology is simple, and cost is low, has reached the best-of-breed technology effect.
The specific embodiment
Below in conjunction with specific embodiment the present invention is described in detail:
Embodiment 1:
Prescription:
Chlorhexidine acetate 200g
Hydroxyethyl-cellulose (HEC) 2000g
Ethanol (95%) 2000g
Lactic acid (left-handed) 3g
Water 95797g
Preparation technology:
Chlorhexidine acetate is added in the ethanol, after stirring and dissolving, place stand-by.
The HEC of recipe quantity is added in the purified water, and heated and stirred is dissolved fully to HEC, is heated to 85 ℃, is incubated 30 minutes.Stir, be cooled to 60 ℃, add lactic acid, adjust pH 5.0-7.0 with 10 times of water gaging dilutions; Stir, be cooled to 45 ℃, add the chlorhexidine acetate alcoholic solution of preparation in advance, be cooled to 35 ℃, stirred 30 minutes, the detection appearance transparent does not have discharging behind the granule, promptly.
Embodiment 2:
Prescription:
Chlorhexidine gluconate 300g
Hydroxypropyl methylcellulose (HPMC) 2000g
Ethanol (95%) 2000g
Lactic acid (left-handed) 3g
Water 95697g
Preparation technology:
Chlorhexidine gluconate is added in the ethanol, after stirring and dissolving, place stand-by.
The HPMC of recipe quantity is added in the purified water, and heated and stirred is dissolved fully to HPMC, is heated to 85 ℃, is incubated 30 minutes.Stir, be cooled to 60 ℃, add lactic acid, adjust pH 5.0-7.0 with 10 times of water gaging dilutions; Stir, be cooled to 45 ℃, add the chlorhexidine gluconate alcoholic solution of preparation in advance, be cooled to 35 ℃, stirred 30 minutes, the detection appearance transparent does not have discharging behind the granule, promptly.
Embodiment 3:
Prescription:
Chlorhexidine acetate 20g
Hydroxyethyl-cellulose (HEC) 2000g
Ethanol (95%) 2000g
Lactic acid (left-handed) 3g
Water 95977g
Preparation technology:
Chlorhexidine acetate is added in the ethanol, after stirring and dissolving, place stand-by.
The HEC of recipe quantity is added purified water, and heated and stirred is dissolved fully to HEC, is heated to 85 ℃, is incubated 30 minutes.Stir, be cooled to 60 ℃, add lactic acid, adjust pH 5.0-7.0 with 10 times of water gaging dilutions; Stir, be cooled to 45 ℃, add the chlorhexidine acetate alcoholic solution of preparation in advance, be cooled to 35 ℃, stirred 30 minutes, the detection appearance transparent does not have discharging behind the granule.Promptly get gel of the present invention.
Embodiment 4:
Prescription:
Chlorhexidine gluconate 900g
Hydroxyethyl-cellulose (HEC) 2000g
Ethanol (95%) 2000g
Lactic acid (left-handed) 3g
Water 95097g
Preparation technology:
Chlorhexidine gluconate is added in 95% ethanol, after stirring and dissolving, place stand-by.
The HEC of recipe quantity is added in the purified water, and heated and stirred is dissolved fully to HEC, is heated to 85 ℃, is incubated 30 minutes.Stir, be cooled to 60 ℃, add lactic acid, tone pitch pH5.0-7.0 with 10 times of water gaging dilutions; Stir, be cooled to 45 ℃, add the chlorhexidine gluconate alcoholic solution of preparation in advance, be cooled to 35 ℃, stirred 30 minutes, the detection appearance transparent does not have discharging behind the granule, promptly.
Embodiment 5:
Stability test 1
Get packaged sample, earlier-5 ℃ of storages 24 hours, take out recover room temperature after, put into 40 ℃ of constant temperature ovens storages 24 hours again, continuous like this carry out three heat-resisting cold-resistant circulations after, recover room temperature.In forward and backward outward appearance, color and luster, fragrance, pH value and the viscosity of detecting respectively of circulation.
Evaluation result before and after table 1 circulation
Evaluation result appearance luster fragrance pH value viscosity (cps)
Gel water white transparency free from extraneous odour 6.2 39000 before the circulation
Circulation back gel water white transparency no change 6.1 38500
The product physical and chemical index did not have significant change, requirement up to specification before and after the result showed circulation.
Stability test 2
Get the good sample of embodiment 1 intermediate package, place in 54 ℃ of calorstats.Use the content of determined by ultraviolet spectrophotometry chlorhexidine respectively at (0 day), placement before placing after 14 days and 30 days.Measurement result is as showing:
Table 2 chlorhexidine stability test result
Place after 14 days before placing and place after 30 days
0.0987% 0.0982% 0.0981%
The result shows that placing the front and back chlorhexidine acetate does not have significant change, requirement up to specification.
Above-mentioned explanation, embodiment and data provide the complete preparation and the purposes of gel of the present invention.Because many specific embodiments are not being violated under character of the present invention and the scope situation and can accomplished, they also should be included in the claim scope of the present invention.

Claims (10)

1. sterilizing gel, it by chlorhexidine or its physiologically acceptable salt and the medicine acceptable carrier that is fit to make gel form.
2. the gel in the claim 1, the physiologically acceptable salt of wherein said chlorhexidine is chlorhexidine acetate and chlorhexidine gluconate.
3. the gel in the claim 1, wherein said carrier comprises forming agent, synergist and pH regulator agent.
4. the gel in the claim 3, wherein said forming agent is selected from one or more in tragakanta, gelatin, starch, cellulose derivative, carbopol and the sodium alginate.
5. the gel in the claim 3, wherein said synergist is selected from ethanol, isopropyl alcohol, propylene glycol and pentanediol.
6. the gel in the claim 3, wherein said pH regulator agent is selected from lactic acid, citric acid, tartaric acid, malic acid, succinic acid, 1,3-propanedicarboxylic acid, maleic acid, glutamic acid, mandelic acid, fumaric acid, one or more in the phosphoric acid.
7. the gel in the claim 4, wherein said cellulose derivative is selected from hydroxyethyl-cellulose, hydroxypropyl methylcellulose.
8. the gel in the claim 1, by chlorhexidine or its physiologically acceptable salt and hydroxyethyl-cellulose, ethanol, lactic acid is formed, wherein, chlorhexidine or its physiologically acceptable salt account for the 0.01%-5% of total formulation weight amount, and hydroxyethyl-cellulose accounts for the 0.2%-20% of total formulation weight amount, ethanol accounts for the 0.2-20% of total formulation weight amount, and lactic acid accounts for the 0.001-0.1% of total formulation weight amount.
9. the gel in the claim 1, by chlorhexidine or its physiologically acceptable salt and hydroxypropyl methylcellulose, ethanol, lactic acid is formed, wherein, chlorhexidine or its physiologically acceptable salt account for the 0.01%-5% of total formulation weight amount, and hydroxypropyl methylcellulose accounts for the 0.2%-20% of total formulation weight amount, ethanol accounts for the 0.2-20% of total formulation weight amount, and lactic acid accounts for the 0.001-0.1% of total formulation weight amount.
10. the gel in the claim 8 or 9, wherein, chlorhexidine or its physiologically acceptable salt account for the 0.5-5% of total formulation weight amount, hydroxypropyl methylcellulose or hydroxyethyl-cellulose account for the 0.5-5% of total formulation weight amount, ethanol accounts for the 0.5-5% of total formulation weight amount, and lactic acid accounts for the 0.002-0.01% of total formulation weight amount.
CNB2005100539041A 2005-03-11 2005-03-11 Sterilizing gel Expired - Fee Related CN1301106C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2005100539041A CN1301106C (en) 2005-03-11 2005-03-11 Sterilizing gel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2005100539041A CN1301106C (en) 2005-03-11 2005-03-11 Sterilizing gel

Publications (2)

Publication Number Publication Date
CN1682703A true CN1682703A (en) 2005-10-19
CN1301106C CN1301106C (en) 2007-02-21

Family

ID=35262324

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100539041A Expired - Fee Related CN1301106C (en) 2005-03-11 2005-03-11 Sterilizing gel

Country Status (1)

Country Link
CN (1) CN1301106C (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101310702B (en) * 2007-05-25 2011-10-26 上海利康消毒高科技有限公司 Emulsion type gel preparation containing chlorhexidine and alcohol
CN103463140A (en) * 2013-09-22 2013-12-25 汤永强 Disinfection repairing liquid
CN109692128A (en) * 2018-12-20 2019-04-30 扬州倍加洁日化有限公司 A kind of antibacterial wet tissue and its production method
CN106176398B (en) * 2016-08-18 2019-11-19 吉安市御美丽健康产业股份有限公司 A kind of women repairs the preparation method of liquid
CN111434334A (en) * 2019-01-11 2020-07-21 李可 Female gel

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3376957D1 (en) * 1982-06-24 1988-07-14 Robert Alan Smith Pharmaceutical gel composition
JP2533723B2 (en) * 1992-12-28 1996-09-11 東興薬品工業株式会社 Quick-drying gel type hand sanitizer
CN1077373A (en) * 1993-04-06 1993-10-20 王师舜 Sex emollient disinfectant
CN1090205A (en) * 1993-09-01 1994-08-03 林亚萍 The preparation method of aquogel with polyvinyl alcohol support and product
GB9408545D0 (en) * 1994-04-29 1994-06-22 Zyma Sa Compositions

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101310702B (en) * 2007-05-25 2011-10-26 上海利康消毒高科技有限公司 Emulsion type gel preparation containing chlorhexidine and alcohol
CN103463140A (en) * 2013-09-22 2013-12-25 汤永强 Disinfection repairing liquid
CN106176398B (en) * 2016-08-18 2019-11-19 吉安市御美丽健康产业股份有限公司 A kind of women repairs the preparation method of liquid
CN109692128A (en) * 2018-12-20 2019-04-30 扬州倍加洁日化有限公司 A kind of antibacterial wet tissue and its production method
CN111434334A (en) * 2019-01-11 2020-07-21 李可 Female gel

Also Published As

Publication number Publication date
CN1301106C (en) 2007-02-21

Similar Documents

Publication Publication Date Title
EP3520785B1 (en) Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use
US6440949B1 (en) Method for promoting the growth of gram-positive bacilli and increasing the acidity in vagina
JP2005511642A5 (en)
CN1301106C (en) Sterilizing gel
CN100457084C (en) Nanometer silver type external use antibiotic gel for female external use and its prepn. method
AU2005257722A1 (en) Composition comprising lactic acid and lactoferrin
CN105126107A (en) Liquid wound dressing
CN102028705A (en) Gynecologic article containing biological antifungal components
CN1823813A (en) Nursing and treating composition for female vagina and its preparation method
CN108420789A (en) A kind of benzalkonium chloride externally used solution and preparation method thereof
CN110743003A (en) anti-HPV type vaginal temperature-sensitive gel, preparation method and application thereof
CN102048729B (en) Preparation for treating vaginitis
CN104069124A (en) Composition and preparation for gynecologic infections
CN107811964A (en) Antibacterial conception control gel that is biodegradable and realizing dosed administration
CN111905058A (en) Pharmaceutical composition for skin mucosa nursing and wound repair and preparation method thereof
CN102000092B (en) New application of sulfadiazine sodium in preparing medicine for preventing or treating Bombyx mori septicemia
CN101766813A (en) Suppository for treating mammalian endometritis and preparation method thereof
CN1911441A (en) Lysostaphin freeze dried powder used for preventing and treating cattle edometritis
CN111329846A (en) Vaginal sterilization adhesive film and preparation method thereof
WO2017193509A1 (en) Bionic gynecological lotion and preparation method therefor
CN101797374A (en) Compound minocycline hydrochloride soluble powder for treating respiratory diseases of poultry
CN111588773B (en) Traditional Chinese medicine composition for preventing and treating newborn piglet diarrhea through sow medicine taking and application thereof
CN106974926B (en) A kind of pharmaceutical composition and its preparation method and application for treating pressure sore
CN1297563C (en) Clindamycin and metronidazole pessary
CN108096182A (en) Gynecological antibacterial gel based on green antibacterial material and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070221

Termination date: 20100311